Patent application number | Description | Published |
20130164796 | SYSTEMS AND METHODS FOR CONTAMINANT REMOVAL FROM A MICROALGAE CULTURE - Systems and methods for the removal of contaminants from a liquid culture microalgae and/or cyanobacteria comprise an let tube, a pump, a gas injector, a vertical chamber, and/or a collection container that promotes the production of foam in the microalgae culture, wherein the foam contains the contaminants. | 06-27-2013 |
20130164824 | SYSTEMS AND METHODS FOR CONTAMINANT REMOVAL FROM A MICROALGAE CULTURE - Systems and methods for the removal of contaminants from a liquid culture microalgae and/or cyanobacteria comprise an inlet tube, a pump, a gas injector, a vertical chamber, and/or a collection container that promotes the production of foam in the microalgae culture, wherein the foam contains the contaminants. | 06-27-2013 |
20130164834 | SYSTEMS AND METHODS FOR CONTAMINANT REMOVAL FROM A MICROALGAE CULTURE - Systems and methods for the removal of contaminants from and transferring gasses within a liquid culture microalgae and/or cyanobacteria comprise an inlet tube, a pump, a gas injector, a vertical chamber, and/or a collection container that promotes the production of foam in the microalgae culture, wherein the gasses may be added to or removed from the liquid culture. | 06-27-2013 |
20130164835 | SYSTEMS AND METHODS FOR CONTAMINANT REMOVAL FROM A MICROALGAE CULTURE - Systems and methods for the removal of contaminants from a liquid culture microalgac and/or cyanobacteria comprise an inlet tube, a pump, a gas injector, a vertical chamber, and/or a collection container that promotes the production of foam in the microalgae culture, wherein the foam contains the contaminants. | 06-27-2013 |
20130164836 | SYSTEMS AND METHODS FOR CONTAMINANT REMOVAL FROM A MICROALGAE CULTURE - Systems and methods for the removal of contaminants from a liquid culture microalgae and/or cyanobacteria comprise an inlet tube, a pump, a gas injector, a vertical chamber, and/or a collection container that promotes the production of foam in the microalgae culture, wherein the foam contains the contaminants. | 06-27-2013 |
Patent application number | Description | Published |
20100226858 | METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION - The present invention describes an association between genetic polymorphisms in the ceramide kinase-like (CERKL) gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation. | 09-09-2010 |
20100249188 | PREDICTION OF QT PROLONGATION BASED ON SNP GENOTYPE - The present invention relates to the prediction of QT prolongation following administration of a compound capable of increasing an individual's QT interval based on the individual's genotype at one or more single nucleotide polymorphism (SNP) loci and to the treatment of a patient based on such prediction. | 09-30-2010 |
20110021566 | GENETIC MARKERS FOR EFFICACY OF ILOPERIDONE IN THE TREATMENT OF PSYCHOTIC SYMPTOMS - Methods for predicting whether iloperidone will be efficacious in treating a psychotic symptom in an individual, based on the individual's genotype at one or more single nucleotide polymorphism (SNP) loci are described, as are methods for treating an individual based on such prediction. | 01-27-2011 |
20110118313 | IDENTIFICATION OF A MOLECULAR SIGNATURE FOR ANTIPSYCHOTICS AND SERMS - Molecular signature for antipsychotics and SERMs has been identified, namely their upregulation of genes that alter lipid homeostasis, preferably of one or more of the following genes: TNSIG1, SCD, FADS2, LDLR, FDPS, ACAT2, FDFT1, CYP51A1, FASN, DHCR7, RAB26, TM7SF2, SATB1, FAM117, GPNMB, NUPR1, VAC14, and LSS. | 05-19-2011 |
20120035215 | METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION - The present invention describes an association between genetic polymorphisms in the ABCC2 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation. | 02-09-2012 |
20120058201 | METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION - The present invention describes an association between genetic polymorphisms in the FAM13A1 (family with sequence similarity 13, member A1) gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval- prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation. | 03-08-2012 |
20120059035 | METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION - The present invention describes an association between genetic polymorphisms in the BAI3 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation. | 03-08-2012 |
Patent application number | Description | Published |
20150225793 | METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION - The present invention describes an association between genetic polymorphisms in the FAM13A1 (family with sequence similarity 13, member A1) gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation. | 08-13-2015 |
20150225794 | METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION - The present invention describes an association between genetic polymorphisms in the ABCC2 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation. | 08-13-2015 |
20150225795 | METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION - The present invention describes an association between genetic polymorphisms in the BAI3 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation. | 08-13-2015 |
Patent application number | Description | Published |
20130197076 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS - Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm. | 08-01-2013 |
20140296330 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS - Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm. | 10-02-2014 |
20140296331 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS - Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm. | 10-02-2014 |
20140296332 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS - Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm. | 10-02-2014 |
20140357710 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS - Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm. | 12-04-2014 |
20150025086 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS - Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm. | 01-22-2015 |
20150216837 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS - Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm. | 08-06-2015 |